Open AccessAntitumor immunity by a dendritic cell vaccine encoding secondary lymphoid chemokine and tumor lysate on murine prostate cancer
Author(s) -
Lu Jun,
Zhang Qi,
Liang ChunMin,
Xia ShuJie,
Zhong CuiPing,
Wang DaWei
Publication year - 2008
Publication title -
asian journal of andrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.701
H-Index - 74
eISSN - 1745-7262
pISSN - 1008-682X
DOI - 10.1111/j.1745-7262.2008.00431.x
Subject(s) - dendritic cell , cancer research , prostate cancer , biology , cd8 , chemokine , immunology , immune system , cancer , genetics
Aim: To investigate the antitumor immunity by a dendritic cell (DC) vaccine encoding secondary lymphoid chemokine gene and tumor lysate on murine prostate cancer. Methods: DC from bone marrow of C57BL/6 were transfected with a plasmid vector expressing secondary lymphoid chemokine (SLC) cDNA by Lipofectamine2000 liposome and tumor lysate. Total RNA extracted from SLC+lysate–DC was used to verify the expression of SLC by reverse transcriptase‐polymerase chain reaction (RT‐PCR). The immunotherapeutic effect of DC vaccine on murine prostate cancer was assessed. Results: We found that in the prostate tumor model of C57BL/6 mice, the adminstration of SLC+lysate–DC inhibited tumor growth most significantly when compared with SLC–DC, lysate–DC, DC or phosphate buffer solution (PBS) counterparts ( P < 0.01). Immunohistochemical fluorescent staining analysis showed the infiltration of more CD4 + , CD8 + T cell and CD11c + DC within established tumor treated by SLC +lysate–DC vaccine than other DC vaccines ( P < 0.01). Conclusion: DC vaccine encoding secondary lymphoid chemokine and tumor lysate can elicit significant antitumor immunity by infiltration of CD4 + , CD8 + T cell and DC, which might provide a potential immunotherapy method for prostate cancer.